Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Pavel, M; Singh, S; Strosberg, J; Bubuteishvili-Pacaud, L; Degtyarev, E; Neary, M; Carnaghi, C; Tomasek, J; Wolin, E; Raderer, M; Lahner, H; Valle, Juan W; Pommier, R; Van Cutsem, E; Tesselaar, M; Fave, G; Buzzoni, R; Hunger, M; Eriksson, J; Cella, D; Ricci, J; Fazio, N; Kulke, M; Yao, J

Affiliation

Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

Issue Date

2017-08-21

Metadata

Show full item record

Abstract

In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint.

Citation

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2017 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/620568

DOI

10.1016/S1470-2045(17)30471-0

PubMed ID

28838862

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications